Thus, the results of in vitro study indicate the effectiveness of reprogramming to achieve the resistance of CD3+CD8+ T-lymphocytes of volunteer’s blood to the cytotoxic effect of tumor cells of a patient with SCLC. The gene discussed is CD8A; the disease is small cell lung carcinoma.